Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient
- 23 November 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 21 (12) , 1543-1552
Abstract
Liver transplantation can provide definitive cure for patients with cirrhosis and hepatocellular carcinoma (HCC) when used appropriately. Advances in the management of HCC have allowed improved control of HCC while waiting for liver transplantation and new approaches to candidate selection particularly with regard to tumor burden and downstaging protocols. Additionally, there have been recent changes in allocation policy related to HCC in the U.S. that cap the HCC MELD exception at 34 points and implement a 6‐month delay in a HCC MELD exception. This review examines the U.S. liver transplant allocation policy related to HCC, comprehensively details locoregional therapy options in HCC patients awaiting liver transplantation, and considers the impact of an increasing burden of HCC on future liver graft allocation policy. Liver Transpl 21:1543‐1552, 2015. © 2015 AASLD.Keywords
This publication has 71 references indexed in Scilit:
- Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic FactorsAmerican Journal of Gastroenterology, 2012
- Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control studyWorld Journal of Surgical Oncology, 2012
- Nonalcoholic Steatohepatitis and Noncirrhotic Hepatocellular Carcinoma: Fertile SoilSeminars in Liver Disease, 2012
- Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference reportThe Lancet Oncology, 2012
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitisJournal of Gastroenterology, 2009
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapyHepatology, 2009
- Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies #Hepatology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Liver Transplantation Criteria For Hepatocellular Carcinoma Should Be ExpandedAnnals of Surgery, 2007